Business
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Astra-Merck and AstraZeneca PLCProven leader in late-stage clinical development, global commercialization, and capital formation across central nervous system (“CNS”) programsAppointed as Helus Pharma advances its pipeline toward key clinical milestones, including expected Phase 2
About this update from Cboe Global Markets, Inc.
[{"type":"image","alt":"Helus Pharma","displaySize":"","headline":null,"caption":"Helus Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":158,"url":"https://media.zenfs.com/en/globenewswire.com/686bbe5b91123e89e8409b06693f4c30"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6x1COZztNjTZXG58YJxcSw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/686bbe5b91123e89e8409b06693f4c30","width":300,"height":158}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Astra-Merck and AstraZeneca PLC","length":249,"tagName":"p"}]},{"val":[{"type":"text","content":"Proven leader in late-stage clinical development, global commercialization, and capital formation across central nervous system (“CNS”) programs","length":144,"tagName":"p"}]},{"val":[{"type":"text","content":"Appointed as Helus Pharma advances its pipeline toward key clinical milestones, including expected Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 later this year","length":187,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":580,"olType":false},{"type":"text","content":"This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.","length":235,"tagName":"p"},{"type":"text","content":"BOSTON and TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (“Helus”) (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced the appointment of Michael Cola as Chief Executive Officer, effective immediately.","length":339,"tagName":"p"},{"type":"text","content":"Mr. Cola’s appointment comes at a pivotal moment as Helus advances its pipeline of next-generation mental health therapies toward key clinical and corporate value-inflection milestones, including the expected release of Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 in Q4 20...